Lantheus Medical Imaging, Inc.
331 Treble Cove Road
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.
Mary Anne Heino
President and Chief Executive Officer
Chief Financial Officer and Treasurer
Senior Vice President, Technical Operations
Senior Vice President - Law and Public Policy, General Counsel and Secretary
Sarah Le Roy
Senior Vice President, Human Resources
Senior Vice President, Corporate Development
Cesare Orlandi, M.D.
Chief Medical Officer
Senior Vice President, Research and Pharmaceutical Development
Senior Vice President, Quality
115 articles with Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging Announces Appointment of Cesare Orlandi, M.D., as New Chief Medical Officer
Lantheus Medical Imaging Announces FDA Approval of Jubilant HollisterStier as a New Manufacturing Site for DEFINITY®
Lantheus Medical Imaging and FUJIFILM RI Pharma Renew Long-Term License and Distribution Agreement for Cardiolite and Neurolite in Japan
Lantheus Medical Imaging to Host Third Quarter 2012 Conference Call on November 13, 2012 at 4:00 P.M. Eastern Time
Lantheus Medical Imaging Extends Contract With NTP Radioisotopes to Ensure Robust Supply of LEU-Produced Molybdenum-99
Lantheus Medical Imaging to Present at Imperial Capital Global Opportunities Conference on September 20, 2012
Lantheus Medical Imaging to Host Second Quarter 2012 Conference Call on August 16, 2012 at 4:00 P.M. Eastern Time
Lantheus Medical Imaging Announces Appointment of Michael W. Heslop as Vice President, International
Lantheus Medical Imaging Release: CaRES Study Published in the Journal of the American Society of Echocardiography Further Demonstrates the Safety and Tolerability of Ultrasound Contrast Agent DEFINITY® in a Large and Diverse Patient Population
Lantheus Medical Imaging Selected to Receive $300,000 Massachusetts-Israel Innovation Partnership Grant
Lantheus Medical Imaging to Host First Quarter 2012 Conference Call on May 23, 2012 at 4:00 p.m. Eastern Time
Lantheus Medical Imaging Announces Manufacturing and Supply Agreements With Jubilant HollisterStier LLC for Cardiolite®and Neurolite®